EQT

Avidicure is a biotechnology company developing a dual agonistic, multifunctional antibody modality engineered for targeted cancer immunotherapy. Its AVC-Boosters are designed to engage immune cells with high avidity and to localize activation within tumors, enabling potent anti-tumor activity as monotherapy while reducing off-target effects. The approach aims to advance oncology therapies by combining immune engagement with tumor-specific activation to support immune responses and potentially improve safety profiles.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

Cornerstone Robotics develops medical robotic devices designed for precise surgical robotic systems. Their products feature multi-degree-of-freedom robotic arms, real-time imaging integration, and intuitive surgeon interfaces, enabling healthcare providers to perform advanced minimally invasive surgeries with greater control and consistency.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Founded in 2019, Noema Pharma is a biotechnology company based in Basel, Switzerland. It specializes in developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks, aiming to improve patient outcomes and quality of life.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

NUA Surgical is an award-winning company based in Galway, Ireland, developing and manufacturing surgical instruments for obstetrics and gynecology. Its patented disposable C-section retractor is designed to improve ergonomics and safety during caesarean deliveries, aiming to reduce complications and support safer care for mothers and infants.

ATB Therapeutics is a biopharmaceutical company that provides novel therapeutic solutions and treatments for cancer patients.

GeBBS Healthcare Solutions is a technology-enabled company that provides revenue cycle management (RCM) solutions to improve financial performance, compliance, and patient satisfaction. Founded in 2005 and headquartered in Culver City, California, GeBBS offers a range of services including Health Information Management (HIM), Revenue Cycle Management (RCM), Patient Access, Risk Adjustment Solutions, strategic outsourcing, and consulting services. The company serves hospitals, physician groups, health plans, and medical billing companies. With over 6,000 employees globally, GeBBS has formed strategic partnerships with various industry associations and organizations.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

QurAlis Corporation is a Cambridge, Massachusetts-based clinical-stage biotechnology company developing precision therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. It focuses on drugs that directly target disease-causing genetic alterations using proprietary platforms and biomarkers to identify and treat patients with specific genetic mutations, aiming to halt disease progression and improve outcomes.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Ariceum Therapeutics is a clinical-stage radiopharmaceutical company that focuses on the detection and targeted treatment of aggressive cancers, particularly neuroendocrine tumors and other challenging malignancies. The company's lead product, 177Lu-satoreotide tetraxetan (Satoreotide), acts as an antagonist of the somatostatin type 2 receptor (SSTR2), which is commonly overexpressed in many neuroendocrine tumors. Ariceum is developing Satoreotide as a theranostic pair, which allows for both the diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, certain aggressive tumors, and childhood cancers. This approach aims to provide treatment options for conditions that currently have limited therapies and poor prognoses, enabling healthcare professionals to deliver more effective treatments with reduced side effects.

Founded in 2018, Perfuze is a medical device company based in Galway, Ireland. It specializes in developing catheter-based aspiration technology designed to treat acute ischemic stroke efficiently and effectively.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

3Shape is a global leader in digital dentistry, specializing in advanced intraoral scanning solutions and software for computer-aided design (CAD) and computer-aided manufacturing (CAM). The company offers a comprehensive range of products, including 3D scanners, lab scanners, and cone-beam computed tomography (CT) scanners, which serve both dental and audio industries. With its innovative technology, 3Shape enables dental and hearing professionals to enhance treatment planning and visualization, thereby improving patient care and efficiency. Operating in over 100 countries, the company is committed to providing state-of-the-art solutions that empower practitioners to deliver superior results.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Icon Group specializes in comprehensive cancer care services globally, offering medical and radiation oncology, hematology, health screening, pharmacy, chemotherapy, and compounding.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Founded in 2020, Egle Therapeutics is a biotechnology company based in Paris, France. It specializes in developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Visus Therapeutics is a clinical-stage company developing innovative ophthalmic therapies to improve vision worldwide. Its primary focus is on creating eye drops for correcting presbyopia, with additional product candidates targeting ocular surface disease, glaucoma, and age-related macular degeneration.

Meine Radiologie Holding GmbH is a provider of radiological and radiotherapy treatment services focused on imaging diagnostics. The company specializes in offering radiology diagnostics and radiation treatments for both malignant and benign conditions. Additionally, it supports radiological and nuclear medicine practices by acting as a financial investor and professional management partner, particularly in succession planning. Through its services, Meine Radiologie Holding aims to create added value for doctors, employees, referrers, and patients by optimizing both central and local processes within the healthcare framework.

Muna Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies aimed at slowing or halting devastating neurodegenerative diseases such as Parkinson's, Alzheimer's, Frontotemporal Dementia, and Multiple Sclerosis.

The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Cerba HealthCare S.A.S. is a clinical pathology laboratory that offers a range of routine and specialized laboratory testing services. The company operates a network of medical laboratories that serve a diverse clientele, including private patients, physicians, hospitals, retirement and nursing homes, as well as pharmaceutical and biotech companies. Cerba HealthCare focuses on both standard laboratory tests and more complex specialty testing, enabling clients to interpret and analyze test results effectively. This comprehensive approach aids in the monitoring of patient health and provides significant insights based on clinical context, enhancing the decision-making process for healthcare providers.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Founded in 2015, Neurent Medical is a medical device company based in Galway, Ireland. It specializes in developing non-surgical treatments for chronic rhinitis using minimally invasive, hand-held radio-frequency devices.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

LUMA Vision develops connected intravascular medical devices to support the treatment of cardiac arrhythmias. Using advanced four-dimensional imaging and artificial intelligence with real-time tissue analysis, the company enhances electrophysiology and structural heart interventions, aiming to improve patient outcomes, increase procedural safety, and reduce healthcare system costs.

Schülke & Mayr GmbH, founded in 1889 and headquartered in Norderstedt, Germany, specializes in developing and manufacturing a wide range of hygiene and infection prevention products. The company's offerings include disinfectants, antiseptics, preservatives, biocides, medical skin care products, and active ingredients for deodorants and system cleaners. Schülke & Mayr provides tailored hygiene management solutions to combat hospital-acquired infections and supplies professional hygiene products for medical practices, outpatient surgery departments, and day clinics. Additionally, the company addresses industrial hygiene needs across various sectors, including food processing and the production of sterile medicinal products, along with offering preservatives for cosmetics and household products. Its global presence includes subsidiaries in several countries, enabling it to serve diverse industries such as healthcare, dental, food, pharmaceuticals, cosmetics, and metalworking. The company operates as a subsidiary of L'Air Liquide S.A.

Galderma is a global dermatology company founded in 1981 as a joint venture between Nestlé and L’Oréal. It later operated as Nestlé Skin Health before being carved out and launched as a standalone company in 2019, and it was listed on the SIX Swiss Exchange in March 2024. The company develops and markets science-based solutions across injectable aesthetics, dermatological skincare, and therapeutic dermatology, addressing conditions such as acne, rosacea, psoriasis and pigmentary disorders, skin cancer, and skin aging. Its products are sold in about 80 countries through a worldwide network of affiliates and distributors, supported by thousands of employees. The brand portfolio includes dermatology and aesthetic products such as Differin, Cetaphil, Restylane, Emervel, Mirvaso, Loceryl, and Metvix, among others.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

DNA Script is a Paris-based company that develops synthetic biology tools focused on DNA synthesis. It employs enzymatic processes to produce synthetic nucleic acids, including oligonucleotides, enabling genomics and molecular biology applications. Founded in 2014, it introduced the SYNTAX benchtop DNA printer to provide labs with greater workflow control and faster access to results. By producing DNA through natural enzymes, the company aims to accelerate research and the development of new therapeutics.

Igenomix is a company that offers genetic testing services specifically designed for reproductive health patients and clinics. It focuses on various aspects of reproductive genetics, providing services such as non-invasive prenatal testing, carrier genetic testing, preimplantation genetic diagnosis, and endometrial receptivity assessment. In addition to these testing services, Igenomix is involved in developing tools and solutions aimed at enhancing reproductive medicine. The company addresses key factors related to infertility, including embryonic viability and endometrial receptivity, thereby supporting couples who are trying to conceive. Through its specialized offerings, Igenomix plays a significant role in the field of reproductive health.

SNIPR Biome is a biotechnology company developing CRISPR-based therapies for treating microbial diseases. Founded in 2017 and headquartered in Copenhagen, Denmark, the company leverages CRISPR technology to selectively eliminate harmful bacteria by targeting their specific DNA sequences.

WS Audiology A/S is a manufacturer and distributor of hearing instruments and audiological solutions, headquartered in Lynge, Denmark. Established in 2019 through a partnership between Sivantos and Widex, the company aims to enhance hearing care for individuals with hearing needs. Its product offerings include a comprehensive range of hearing aids, such as receiver-in-the-ear devices, assistive listening devices, and solutions for single-sided deafness. Additionally, WS Audiology provides accessories like hearing aid batteries, remote controls, and electronic drying stations. The company's diverse product spectrum caters to various price categories, ensuring that those with hearing loss have access to effective solutions for improved hearing and understanding.

Karo Pharma is a pharmaceutical company. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices.

XyloCor Therapeutics, Inc. is a biopharmaceutical company specializing in the development of gene therapies for cardiovascular diseases, particularly advanced coronary artery disease. Founded in 2013 and based in Newtown Square, Pennsylvania, the company focuses on innovative treatments aimed at addressing significant unmet medical needs. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, targeting individuals who have exhausted other treatment options. XyloCor's approach centers on stimulating the formation of new coronary blood vessels to enhance blood supply to areas of the heart that are inadequately perfused, thereby improving patient outcomes in those affected by heart failure and ischemic conditions. The company collaborates with Weill Cornell Medical College to advance its gene therapy technologies.

Lumeon Ltd. is a digital health company based in London, United Kingdom, specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and previously known as Qinec Ltd., Lumeon offers a cloud-based platform called Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. The platform enables healthcare providers to unify clinical and administrative workflows, automate tasks, and deliver measurable care, addressing the underlying systems that drive healthcare transformation. Lumeon's clientele includes some of Europe's leading healthcare providers, such as BUPA and Nuffield Health, reflecting its position as a key player in the market. The company employs over 90 professionals dedicated to enhancing patient care through effective management and analysis of healthcare pathways.

Endotronix develops and manufactures implantable wireless pulmonary artery pressure sensors for early detection of worsening heart failure. The company's platform includes a cloud-based disease management data system, enabling remote patient monitoring.

HyTest Ltd. is a manufacturer of monoclonal antibodies and antigens specifically for the diagnostic industry, founded in 1994 and headquartered in Turku, Finland. The company specializes in developing innovative solutions for assay development and research applications, providing a range of products and services that include antibodies, antigens, and various biomarkers. HyTest's offerings are utilized across multiple clinical areas, such as cardiac markers, infectious diseases, metabolic syndrome, and veterinary diagnostics. By focusing on research and development, HyTest enables its clients to deliver accurate testing solutions in the in vitro diagnostic sector.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

3PBiovian is a global Contract Development and Manufacturing Organization (CDMO) specializing in aseptic fill and finish for biopharmaceutical products. Established in 2003, the company offers end-to-end services from early development to finished vial, covering all protein expression systems and viral vectors. Its facilities are EMA certified and FDA inspected.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

Simplify Medical, Inc. is a medical device company specializing in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs intended for spinal use. Founded in 2013 and based in Sunnyvale, California, it offers innovative products such as the Simplify Disc, a non-metallic, MRI-compatible artificial cervical disc that preserves motion while allowing for full diagnostic imaging without the need for traditional CT scans. This technology minimizes patient exposure to ionizing radiation and is tailored for skeletally mature patients undergoing reconstruction at one level from C3 to C7 following discectomy procedures. Simplify Medical markets its products through distributors in the United Kingdom, Germany, and other international markets. The company was previously known as Simplify Delaware, Inc. before rebranding in February 2015.

Luxendo is a company that specializes in the development and manufacture of advanced Single Plane Illumination Microscopes (SPIM), a technology initially developed at the European Molecular Biology Laboratory (EMBL). By utilizing a light-sheet fluorescence microscopy technique, Luxendo's instruments facilitate rapid three-dimensional imaging of living organisms, including spheroids and whole specimens, without the need for sample rotation. This innovative approach allows for gentle handling of delicate samples, such as cell cultures and embryonic specimens, enabling scientists to observe living organisms over extended periods while minimizing photodamage. The company's commitment to revolutionizing bio-imaging positions it as a leader in the field of microscopy, providing researchers with powerful tools for biological exploration.

OxThera AB is a biopharmaceutical company focused on developing innovative therapies for the treatment of primary and secondary hyperoxaluria, a condition that can lead to kidney damage. Founded in 2005 and headquartered in Stockholm, Sweden, with an additional facility in Knoxville, Tennessee, OxThera specializes in products that utilize bacteria and enzymes to manage oxalate levels in the body. Its leading products include Oxabact, an oral formulation of live bacteria designed to enhance the elimination of oxalate produced endogenously, and Oxazyme, a non-systemic oral drug made from recombinant oxalate decarboxylase aimed at treating dietary hyperoxaluria and preventing kidney stones. Oxabact has received Orphan Drug designations in both Europe and the United States, underscoring its potential in addressing unmet medical needs in this therapeutic area. The company holds worldwide patents for its unique compositions and treatment methods targeting hyperoxaluria.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Press Ganey partners with over 10,000 healthcare organizations globally to enhance the quality of care and improve patient experiences. The company provides a range of solutions, including patient-experience measurement, performance analytics, and strategic advisory services, aimed at reducing patient and caregiver suffering while ensuring safety and quality in healthcare delivery. By collaborating with a diverse array of clients, including hospitals, medical practices, and home care agencies, Press Ganey helps organizations operate more efficiently, increase market share, and optimize reimbursement. With its reach extending to approximately 50 percent of all U.S. hospitals, the company is dedicated to fostering high-performing healthcare environments across the continuum of care.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates engineered viral vector vaccines for cancer treatment. The company's innovative platform leverages a portfolio of modified viral vectors, specifically designed for the efficient expression of long strings of tumor neoantigens. This approach is complemented by a toolkit that facilitates the induction of robust antitumor T-cell responses, effectively enhancing cancer-specific cellular immunity in patients. Through its research and development efforts, Nouscom aims to improve cancer treatment outcomes by harnessing the body's immune system to target and combat cancer cells.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Pharvaris is a clinical-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE). Its lead drug candidate, PHA121, is currently in Phase 1 clinical trials.

Lima Corporate is the Italian multinational in orthopaedics and traumatology. Lima Corporate is a maker of orthopedic equipment for doctors and healthcare practitioners. The company provides a variety of orthopedics and traumatology surgical equipment and devices, as well as implantable prostheses for knee, hip, shoulder, and minor joint arthroplasty, allowing clients to receive customised hardware that promotes patient-centered treatment.

Luxendo is a company that specializes in the development and manufacture of advanced Single Plane Illumination Microscopes (SPIM), a technology initially developed at the European Molecular Biology Laboratory (EMBL). By utilizing a light-sheet fluorescence microscopy technique, Luxendo's instruments facilitate rapid three-dimensional imaging of living organisms, including spheroids and whole specimens, without the need for sample rotation. This innovative approach allows for gentle handling of delicate samples, such as cell cultures and embryonic specimens, enabling scientists to observe living organisms over extended periods while minimizing photodamage. The company's commitment to revolutionizing bio-imaging positions it as a leader in the field of microscopy, providing researchers with powerful tools for biological exploration.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Ventaleon is a biopharmaceutical company focused on developing inhaled treatments for viral infections, with a particular emphasis on severe influenza. Its lead therapy, inhaled LASAG, is a lysin-salt formulation of acetylsalicylic acid, designed for use in inhalable aerosol form. Ventaleon's approach allows for a noninvasive method of treatment, which has shown promising results in clinical trials. A proof-of-concept study indicated that patients receiving inhaled LASAG experienced a more rapid decline in symptoms compared to those receiving standard care. The company is currently preparing to initiate a pivotal clinical trial to further evaluate the efficacy of its lead therapy. Founded in 2012 as a spin-off from Activaero, Ventaleon leverages expertise in aerosol inhalation therapies to advance its innovative treatment solutions.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.

Rotation Medical Inc. is a medical technology company based in Plymouth, Minnesota, that specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant system utilizes a collagen scaffold designed to be affixed to the affected rotator cuff tendon, offering a surgical solution for managing and protecting tendon injuries. This system is particularly beneficial for patients with small rotator cuff tears and provides additional protection for those with larger tears. Founded in 2009, Rotation Medical was originally known as Denali Medical Inc. before rebranding in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

I-MED Network Radiology is Australia's largest private medical imaging network, operating over 200 clinics across major metropolitan areas and significant rural regions. Annually, the network conducts over 4 million patient examinations, supported by a team of approximately 300 specialist radiologists, 50 nuclear physicians, and 3,900 staff members. The clinics provide a comprehensive range of radiology services, including X-ray, CT, MRI, nuclear medicine, ultrasound, cardiac imaging, and interventional procedures, ensuring high standards of diagnostic accuracy for referring medical practitioners and patients. Established in 2000 and expanded through a merger with MIA Group Limited in 2004, I-MED remains privately owned and is recognized as one of the largest providers of medical imaging services globally.

Merus is a clinical-stage immuno-oncology company focused on discovering and developing bispecific antibody therapeutics. It utilizes Oligoclonics technology to produce mixtures of human therapeutic antibodies directed to a common antigen from a single cell clone and develops full-length multispecific antibodies known as Biclonics. Merus' pipeline includes bispecific programmes such as MCLA-128, MCLA-117 and MCLA-158, reflecting its emphasis on targeted immune engagement in cancer.

Terveystalo is a Finnish healthcare service provider offering occupational health services, medical care, dental services, and research services. It serves corporate, private, and public sector customers, covering the entire integrated treatment chain of healthcare.

Swiss Smile is a dental service provider based in Switzerland, established in 2003 by Haleh Bronner and Golnar Signer. The company specializes in a comprehensive range of dental treatments that include prevention, preservation, tooth extraction and replacement, teeth straightening, beautification, medical procedures, and hygiene treatments. In addition to these services, Swiss Smile also conducts dentistry classes in schools, promoting dental health education. With operations in several cities including Zurich, Baden, Bulach, St. Moritz, Suhr, and Winterthur, Swiss Smile aims to deliver high-quality dental care to a diverse clientele across the region.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. With nearly two decades of expertise in innate immunity, Affimed seeks to leverage the innate immune system to enhance cancer treatment outcomes. The company specializes in discovering and advancing targeted therapies through its unique approach of using innate cell engagers, which aim to address the limitations of existing immuno-oncology therapies. In addition to its core research and development efforts, Affimed also generates revenue by providing research and development services to third parties, utilizing both its own and externally licensed intellectual property.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

Prosensa, also known as Ribpharm Inc, is a biotech company specializing in the discovery, development, and commercialization of RNA-based therapeutics. The company is particularly focused on addressing genetic disorders, with an emphasis on neuromuscular conditions, as well as anti-infectives and oncology. Prosensa aims to leverage its strong intellectual property position to capitalize on emerging market opportunities in the healthcare sector. To optimize its operations, the company adopts a focused business model by outsourcing most activities to specialized organizations. Through its innovative approach, Prosensa seeks to bring novel and commercially viable therapeutic products to market.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Vivoryon Therapeutics is a biopharmaceutical company focused on developing therapeutic products for the treatment of Alzheimer's disease and cancer. Its lead product candidate, PQ912, has completed Phase IIb clinical trials for Alzheimer's disease. The company also has preclinical development products targeting cancer and is exploring monoclonal antibody therapies.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Mendor is a Finnish company focused on the design, development, and marketing of advanced diabetes management products. It has introduced an innovative all-in-one blood glucose meter and a web-based software application that simplify daily diabetes management. These products are developed in collaboration with users and diabetes experts, ensuring they meet the specific needs of individuals requiring regular blood glucose monitoring. Mendor's patented software systems deliver real-time diabetes care data, enhancing the efficiency and effectiveness of treatment for patients and caregivers alike.

Nexstim specializes in non-invasive brain stimulation technologies, focusing on navigated transcranial magnetic stimulation (TMS) for therapeutic and diagnostic applications. Its proprietary SmartFocus technology enables accurate targeting of specific brain areas. Nexstim's primary products are the NBT system for treating major depression or chronic pain, and the NBS system for pre-surgical brain mapping. Headquartered in Helsinki, Finland, Nexstim serves customers globally.

Argenx is a biopharmaceutical company based in the Netherlands, dedicated to developing antibody-based therapies for rare autoimmune diseases.

Promethera Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver diseases. Founded in 2009 and based in Mont-Saint-Guibert, Belgium, with an office in Tokyo, Japan, the company specializes in cell therapy products, notably HepaStem and H2Stem, which utilize allogeneic progenitor cells derived from healthy human adult livers. Promethera is actively working on treatments for a range of conditions, including acute-on-chronic liver failure, hemophilia, liver fibrosis, non-alcoholic steatohepatitis, liver-based metabolic diseases, and urea cycle disorders. The company also engages in strategic alliances to further its research and development efforts, enhancing its capacity to discover and commercialize effective cell therapies for liver-related ailments.